AC
APTO

Apogem Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Apogem Capital’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23
Closed -$34K – 212
2021
Q2 		$34K Sell
23
-3
-12% -$6.54K 0.02% 188
2021
Q1 		$69K Sell
26
-86
-77% -$171K 0.05% 175
2020
Q4 		$221K Buy
+112
New +$263K 0.15% 148

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Apogem Capital's APTO Position: Q3 2021 in Review

Apogem Capital sold out of Aptose Biosciences, Inc. (APTO) in Q3 2021, closing a stake of 23 shares — an estimated $34K sold.

Apogem Capital first reported a position in APTO in Q4 2020 and held it in 3 quarters. The position peaked at $221K in Q4 2020. 64 funds tracked by Wall St. Rank hold APTO as of Q3 2021.

  • Apogem Capital reported no remaining Aptose Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
  • Apogem Capital sold 23 Aptose Biosciences, Inc. shares in Q3 2021, an estimated $34K.
  • Apogem Capital first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 3 quarters.
  • Apogem Capital's Aptose Biosciences, Inc. position peaked at $221K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2021.

Based on Apogem Capital's 13F filing for Q3 2021, filed 15 Nov 2021.